Development of an inhaled anti-TSLP therapy for asthma

O’Byrne, Paul M.; Panettieri, Reynold A.; Taube, Christian; Brindicci, Caterina; Fleming, Margaret; Altman, Pablo

doi:10.1016/j.pupt.2022.102184

Cited by 16 publications

(9 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While these IL-33/ST2-targeting biologics have not yet received FDA approval, some are now in phase 3 clinical trials. The drugs that block the TSLP pathway include tezepelumab, which recently received FDA approval for asthma, and ecleralimab (formerly CSJ117), which is an inhaled drug that is in phase 2 clinical trials (ClinicalTrials.gov Identifier: NCT04882124) 151 . Clinical trials on drugs against IL-25 have not yet been conducted.…”

Section: Ilc-targeting Therapeutic Applications: Current Methodologie...mentioning

confidence: 99%

Versatile roles of innate lymphoid cells at the mucosal barrier: from homeostasis to pathological inflammation

Ryu,

Lim,

Kim

et al. 2023

Exp Mol Med

View full text Add to dashboard Cite

Innate lymphoid cells (ILCs) are innate lymphocytes that do not express antigen-specific receptors and largely reside and self-renew in mucosal tissues. ILCs can be categorized into three groups (ILC1–3) based on the transcription factors that direct their functions and the cytokines they produce. Their signature transcription factors and cytokines closely mirror those of their Th1, Th2, and Th17 cell counterparts. Accumulating studies show that ILCs are involved in not only the pathogenesis of mucosal tissue diseases, especially respiratory diseases, and colitis, but also the resolution of such diseases. Here, we discuss recent advances regarding our understanding of the biology of ILCs in mucosal tissue health and disease. In addition, we describe the current research on the immune checkpoints by which other cells regulate ILC activities: for example, checkpoint molecules are potential new targets for therapies that aim to control ILCs in mucosal diseases. In addition, we review approved and clinically- trialed drugs and drugs in clinical trials that can target ILCs and therefore have therapeutic potential in ILC-mediated diseases. Finally, since ILCs also play important roles in mucosal tissue homeostasis, we explore the hitherto sparse research on cell therapy with regulatory ILCs. This review highlights various therapeutic approaches that could be used to treat ILC-mediated mucosal diseases and areas of research that could benefit from further investigation.

show abstract

Section: Ilc-targeting Therapeutic Applications: Current Methodologie...mentioning

confidence: 99%

Versatile roles of innate lymphoid cells at the mucosal barrier: from homeostasis to pathological inflammation

Ryu,

Lim,

Kim

et al. 2023

Exp Mol Med

View full text Add to dashboard Cite

show abstract

“…Together, these data suggest that the balance between T2 inflammation and type I interferon/IRF7 responses may stem from the bone marrow, far from the site of peripheral inflammation, as reported in other contexts ( 56 ). They also highlight the potential for new biologic drugs targeting TSLP ( 57 , 58 ) and the downstream effectors IL-13 and IL-17A ( 59 ) to attenuate inflammatory responses to RSV infection in early life.…”

Section: Interferon Response Patterns and The Lung-blood-bone Marrow ...mentioning

confidence: 99%

Emerging role for interferons in respiratory viral infections and childhood asthma

Bosco

2023

Front. Immunol.

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) and Rhinovirus (RV) infections are major triggers of severe lower respiratory illnesses (sLRI) in infants and children and are strongly associated with the subsequent development of asthma. Decades of research has focused on the role of type I interferons in antiviral immunity and ensuing airway diseases, however, recent findings have highlighted several novel aspects of the interferon response that merit further investigation. In this perspective, we discuss emerging roles of type I interferons in the pathogenesis of sLRI in children. We propose that variations in interferon response patterns exist as discrete endotypes, which operate locally in the airways and systemically through a lung-blood-bone marrow axis. We discuss new insights into the role of interferons in immune training, bacterial lysate immunotherapy, and allergen-specific immunotherapy. Interferons play complex and diverse roles in the pathogenesis of sLRI and later asthma, providing new directions for mechanistic studies and drug development.

show abstract

“…There are also the TSLP-pathway inhibitors tezepelumab, which has received Food and Drug Administration (FDA)-approval for asthma, and ecleralimab, an inhaled drug, is in phase-2 clinical trials ( 5 ). Moreover, Abs that specifically target TSLP have shown promise in reducing allergen-induced bronchoconstriction and airway eosinophilia in individuals with allergies, both before and after allergen exposure ( 90 ).…”

Section: Advances In Therapeutic Strategies For Type-2 Immune Diseasesmentioning

confidence: 99%

Innate Type-2 Cytokines: From Immune Regulation to Therapeutic Targets

Kim,

Jeong,

Kim

et al. 2024

Immune Netw

View full text Add to dashboard Cite

The intricate role of innate type-2 cytokines in immune responses is increasingly acknowledged for its dual nature, encompassing both protective and pathogenic dimensions. Ranging from defense against parasitic infections to contributing to inflammatory diseases like asthma, fibrosis, and obesity, these cytokines intricately engage with various innate immune cells. This review meticulously explores the cellular origins of innate type-2 cytokines and their intricate interactions, shedding light on factors that amplify the innate type-2 response, including TSLP, IL-25, and IL-33. Recent advancements in therapeutic strategies, specifically the utilization of biologics targeting pivotal cytokines (IL-4, IL-5, and IL-13), are discussed, offering insights into both challenges and opportunities. Acknowledging the pivotal role of innate type-2 cytokines in orchestrating immune responses positions them as promising therapeutic targets. The evolving landscape of research and development in this field not only propels immunological knowledge forward but also holds the promise of more effective treatments in the future.

show abstract

Development of an inhaled anti-TSLP therapy for asthma

Cited by 16 publications

References 118 publications

Versatile roles of innate lymphoid cells at the mucosal barrier: from homeostasis to pathological inflammation

Versatile roles of innate lymphoid cells at the mucosal barrier: from homeostasis to pathological inflammation

Emerging role for interferons in respiratory viral infections and childhood asthma

Innate Type-2 Cytokines: From Immune Regulation to Therapeutic Targets

Contact Info

Product

Resources

About